Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Travere Therapeutics Inc. Common Stock — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $9.99 (market cap $127.56B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 26.1× Travere Therapeutics Inc. Common Stock's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.73% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MFG | TVTX | |
|---|---|---|
Market Cap | $127.56B | $4.88B |
Volume | 2,374,252 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $11.45 | $67.52 |
52-Week Low | $6.23 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $34.95T | $5.01B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mizuho Financial Group (MFG) trades at $10.60, up slightly by 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.22 exceeding the $0.17 estimate. Revenue grew to $3.65T in 2025, with a net income margin of 30.42% and a P/E ratio of 14.96, indicating reasonable valuation. Recent news highlights institutional stake adjustments and positive CRA ratings.
MFG presents a mixed outlook; earnings momentum and solid profitability support upside, but bearish technicals and analyst caution (60% hold rating) suggest near-term pressure. Key risks include declining cash flow trends and rising debt-to-asset ratio, while institutional interest and dividend growth potential offer opportunities for long-term investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mizuho Financial Group Inc. Sponosred ADR (Japan)
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
